Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

HIV remission

  • Home
  • HIV remission
Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115
Posted inHIV/AIDS news Pediatrics

Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115

Posted by MedXY By MedXY 11/12/2025
IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardized biomarkers are essential.
Read More
  • Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT
  • Cardiomyopathy Gene Therapy Reaches an Inflection Point: From AAV Delivery to Precision Genome Editing
  • Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
  • Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury
  • Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in